Emend Shortage Update: What Patients Need to Know in 2026

For cancer patients who rely on Emend (aprepitant) to manage chemotherapy-induced nausea and vomiting, supply issues have been a source of significant stress. Below is an up-to-date summary of the Emend shortage situation heading into 2026—and what it means for you.

Is Emend Still in Shortage in 2026?

As of early 2026, Emend (aprepitant) is not listed on the FDA's active drug shortage database. The European Medicines Agency (EMA) marked the Emend powder-for-oral-suspension shortage—which affected 80 mg and 125 mg strengths and was first noted in April 2024—as resolved by October 2025.

In the U.S., generic aprepitant is now produced by multiple manufacturers, which has significantly improved national supply. However, this doesn't mean every pharmacy near you has it. Localized stock gaps, especially for less common strengths or formulations, remain an ongoing reality for many patients.

A Brief History of the Emend Shortage

The American Society of Health-System Pharmacists (ASHP) documented a shortage of Emend capsules. At the time, Merck was the sole supplier of brand-name Emend capsules, and the company cited increased demand—not a manufacturing failure—as the root cause. When a single manufacturer is the only source of a critical medication and demand rises, the math is simple: supply struggles to keep up.

The injectable form of Emend (fosaprepitant) was not affected by the oral capsule shortage, and patients with IV access who received their antiemetics at infusion centers were generally not impacted.

Which Formulations Were Most Affected?

The shortage primarily affected:

Emend capsules (80 mg and 125 mg strengths from Merck) — the most commonly prescribed oral form

Emend powder for oral suspension (80 mg and 125 mg) — used for pediatric patients and adults who cannot swallow capsules; this was the formulation covered by the EMA shortage notice

The 40 mg capsule (used for postoperative nausea prevention) and the injectable fosaprepitant were less affected.

Why Localized Stock Issues Still Happen

Even without an active national shortage, individual pharmacies may not stock Emend or generic aprepitant consistently. The reasons are straightforward:

Emend is used for short cycles rather than as a daily chronic medication—so pharmacies don't always keep large inventories

Smaller retail chains may not stock the 125 mg dose or may only carry one manufacturer's generic version

Regional demand spikes near major cancer treatment centers can temporarily wipe out local stock

Distribution delays from a single generic manufacturer can cause temporary unavailability even without a formal shortage designation

What Patients Should Do Right Now

Don't wait until the day before chemo. Start looking for Emend at least 3-4 days before your treatment cycle.

Use medfinder to check multiple pharmacies at once. medfinder calls pharmacies near your zip code to find which ones can fill your prescription, then texts you the results.

Ask for generic aprepitant by name. Generic versions from multiple manufacturers are widely available and therapeutically identical to brand Emend.

Contact your cancer center's pharmacy. Oncology pharmacies typically maintain dedicated stock of chemotherapy support drugs.

Talk to your oncologist about alternatives. If aprepitant is genuinely unavailable, rolapitant (Varubi) or Akynzeo (netupitant-palonosetron) are guideline-supported alternatives.

The Bigger Picture: Drug Shortages and Cancer Care

Emend's shortage history is part of a broader challenge facing oncology patients: many chemotherapy-related medications are affected by supply chain vulnerabilities. When a single manufacturer dominates production of a critical drug, any disruption—whether from increased demand, raw material shortages, or manufacturing issues—can have outsized effects on patient care. For the full background on why this happens, see our article on why Emend is hard to find.

The most important thing you can do as a patient is plan ahead, know your options, and have a backup plan before each chemo cycle begins.